ABCLAbCellera Biologics Inc.
The schedule
- Mon9Nov
This event marks the release of AbCellera's quarterly earnings for the third quarter of 2026, accompanied by guidance for the next fiscal period. The earnings report is a critical moment for investors as it provides insight into the company's financial performance and future outlook. The outcome of this event is expected to have a significant impact on the stock price, with potential for both upward and downward movement. The market will closely watch the results to gauge the company's progress and strategic direction.
- Tue9Feb
This event represents the release of AbCellera's quarterly earnings for the fourth quarter of 2026, along with guidance for the following fiscal period. The earnings report is a key moment for the company as it provides a comprehensive overview of its financial health and strategic direction. The market will be closely monitoring the results to assess the company's performance and future prospects. The outcome of this event is anticipated to have a substantial impact on the stock price, with potential for both positive and negative movements.
- Mon10May
- Wed4Aug
Past
- Wed9Sep
Actual outcome: Bull · $12.31 at outcome
Stock rose 11.3% from event to outcome date, aligning with the bull trajectory.
AbCellera is set to present at Cantor Fitzgerald, where they will discuss recent developments and their pipeline progress. This presentation offers an opportunity for the company to showcase its advancements and strategic initiatives to potential investors and partners. The event is expected to provide valuable information about the company's current status and future plans, which could influence market sentiment. While the impact is considered medium, the presentation may still have a notable effect on the stock price.
- Mon10Aug
Actual outcome: Bull · $10.61 at outcome
AbCellera announced positive top-line Phase 2 clinical trial results for ABCL635, demonstrating an 83% reduction in menopause hot flashes. The data significantly improved investor sentiment and drove a sharp price increase. The results were well-received and marked a key milestone in the drug's development. [Market retrospective · Short-Term (6–10 days)] Missed anticipation: +99.3% from 2026-07-31 to 2026-08-18 (~6.0σ vs typical 10d vol). Target evaluation date 2026-08-20 (not yet reached as of 2026-08-18). Confidence 95%. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-08-20: +99.3% from 2026-07-31 (~6.0σ). Target date 2026-08-19 reached; move through 2026-08-20 observed. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-08-24: +99.3% from 2026-07-31 (~6.0σ). Target date 2026-08-19 reached; move through 2026-08-24 observed.
AbCellera announced positive top-line Phase 2 clinical trial results for ABCL635, demonstrating an 83% reduction in menopause hot flashes. The data significantly improved investor sentiment and drove a sharp price increase. The results were well-received and marked a key milestone in the drug's development. [Market retrospective · Short-Term (6–10 days)] Missed anticipation: +99.3% from 2026-07-31 to 2026-08-18 (~6.0σ vs typical 10d vol). Target evaluation date 2026-08-20 (not yet reached as of 2026-08-18). Confidence 95%. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-08-20: +99.3% from 2026-07-31 (~6.0σ). Target date 2026-08-19 reached; move through 2026-08-20 observed. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-08-24: +99.3% from 2026-07-31 (~6.0σ). Target date 2026-08-19 reached; move through 2026-08-24 observed.
- Wed5Aug
Actual outcome: Bull · $9.34 at outcome
AbCellera reported Q2 earnings in line with estimates, but the stock surged due to positive Phase 2 trial results for ABCL635, showing significant reduction in menopause hot flashes. The positive clinical data and increased investor optimism about the drug's potential drove the rally, surpassing the bull target.
AbCellera reported Q2 earnings in line with estimates, but the stock surged due to positive Phase 2 trial results for ABCL635, showing significant reduction in menopause hot flashes. The positive clinical data and increased investor optimism about the drug's potential drove the rally, surpassing the bull target.
- Tue28Jul
Actual outcome: Bull · $5.69 at outcome
AbCellera announced a new collaboration with Vertex Pharmaceuticals to discover multispecific T-cell engagers for autoimmune diseases and other conditions. This partnership directly fulfilled expectations for a new drug discovery deal, validating the company's platform and driving a 7.6% rally in the stock.
AbCellera announced a new collaboration with Vertex Pharmaceuticals to discover multispecific T-cell engagers for autoimmune diseases and other conditions. This partnership directly fulfilled expectations for a new drug discovery deal, validating the company's platform and driving a 7.6% rally in the stock.
- Mon11May
Actual outcome: Bull · $5.30 at outcome
AbCellera reported a Q1 revenue beat and a narrower-than-expected loss, alongside positive interim Phase 1 clinical data for its lead program, ABCL635. The combination of better-than-expected financial results and tangible clinical progress in its internal pipeline validated the company's execution capabilities, supporting the stock's move toward the bull target.
AbCellera reported a Q1 revenue beat and a narrower-than-expected loss, alongside positive interim Phase 1 clinical data for its lead program, ABCL635. The combination of better-than-expected financial results and tangible clinical progress in its internal pipeline validated the company's execution capabilities, supporting the stock's move toward the bull target.
